The clinical trial labeled NCT02605486 in Table 1, tested this AR inhibitor and CDK4/6 inhibitor in combination, hypothesizing that the combined effects would have increased efficacy in AR+ BC patients [33]. The gene discussed is CDK4; the disease is breast cancer.